Non-coding RNA: Definition, Types, Functions, and Medical Uses

Definition: Non-coding RNA (ncRNA) is any RNA molecule that is transcribed from DNA but is not translated into a protein. Instead of serving as a protein blueprint, the RNA molecule itself is the functional product, acting as a structural, catalytic or regulatory molecule in the cell.

Non-coding RNA is the broad group of RNA molecules that cells make from DNA but do not use as templates for proteins. In the classical route of molecular biology, a gene is transcribed into messenger RNA, and a ribosome reads that messenger RNA to assemble a protein. Non-coding RNA does not follow this protein-coding route: the transcript folds, pairs with other nucleic acids, or binds proteins, and the RNA molecule itself performs the task.

Some non-coding RNAs are part of the cell's core machinery. Ribosomal RNA and transfer RNA, for example, are essential for protein synthesis. Others regulate when, where and how strongly genes are active. Protein-coding sequences account for only about 2 percent of the human genome, while large portions of the non-protein-coding genome are transcribed into RNA at some point. Not every detected transcript has a proven biological function, but tens of thousands of non-coding RNA genes and transcript candidates have now been catalogued.

For much of the twentieth century, RNA was viewed mainly as a messenger between DNA and protein, and genome regions that did not encode proteins were often poorly understood. That picture changed as researchers began finding functional RNAs outside the protein-coding system. In 1993, a small regulatory RNA, later recognised as the first microRNA, was shown to control developmental timing in the worm Caenorhabditis elegans. In 1998, the discovery of RNA interference showed that double-stranded RNA can trigger sequence-specific gene silencing, a finding recognised with the 2006 Nobel Prize in Physiology or Medicine.

Large-scale sequencing in the 2000s revealed that genomes are widely transcribed, producing far more RNA than protein-coding genes alone could explain. This shifted non-coding RNA from a biological curiosity to a central topic in genomics. The shift also introduced a lasting caution: detecting a transcript is not the same as proving that it has a biological role. For many non-coding RNAs, especially long non-coding RNAs, function must still be demonstrated with targeted experiments rather than inferred from transcription alone.

Non-coding RNAs are made by the same basic transcription process that makes messenger RNA. RNA polymerases copy a DNA template into an RNA strand. The difference is what happens next. A protein-coding transcript is read by a ribosome, whereas a non-coding transcript is processed, folded and used as a molecule in its own right. Many ncRNAs are trimmed, chemically modified or assembled with proteins before they become active.

Their biological versatility comes from two properties. First, RNA can recognise other nucleic acids by Watson–Crick base pairing, the same complementarity that holds the two strands of DNA together. This lets a short RNA identify a target messenger RNA by sequence. Second, RNA can fold into three-dimensional shapes that bind proteins, small molecules or other RNAs, and in some cases catalyse chemical reactions. Together, these properties allow ncRNAs to guide protein complexes, scaffold molecular assemblies, modify other RNAs or tune gene expression.

A clear example is the microRNA pathway. A microRNA gene is transcribed as a hairpin-shaped precursor, then cut down to a roughly 22-nucleotide strand that is loaded into a protein complex called the RNA-induced silencing complex. The microRNA acts as an address label: it base-pairs with complementary sequences in target messenger RNAs, and the complex represses translation or promotes degradation of those transcripts. Because the pairing is often partial, one microRNA can influence many targets, and microRNAs are estimated to affect a large fraction of human messenger RNAs.

Non-coding RNAs are often divided into housekeeping and regulatory groups. Housekeeping ncRNAs are stable, abundant molecules that run core cellular machinery: ribosomal RNA forms the catalytic core of the ribosome, transfer RNA delivers amino acids during protein synthesis, and small nuclear and small nucleolar RNAs help process and chemically modify other RNAs. Regulatory ncRNAs are more diverse and usually control gene expression, genome stability or cell state.

Small regulatory RNAs include microRNAs, small interfering RNAs and PIWI-interacting RNAs, which work with Argonaute or PIWI-family proteins to silence genes or restrain transposable elements. Long non-coding RNAs are usually defined as transcripts longer than about 200 nucleotides that lack clear protein-coding capacity. Circular RNAs form closed loops and are unusually stable. Some transcripts annotated as long non-coding RNAs contain short open reading frames and may produce micropeptides, so annotation can change as experimental evidence improves.

Many non-coding RNAs act as regulators rather than as permanent cell machinery. They can control gene expression by guiding chromatin-modifying complexes to DNA, blocking or promoting translation, triggering degradation of target messenger RNAs, acting as scaffolds or decoys for proteins, and influencing RNA splicing, editing or chemical modification. This gives cells an additional regulatory layer beyond protein-coding genes.

Small RNAs usually regulate genes through sequence recognition. MicroRNAs tune gene expression by partially matching messenger RNAs, while siRNAs usually require near-perfect complementarity and can cut a chosen target with high specificity. Long non-coding RNAs often work through more varied mechanisms. Some stay near the genomic region where they are made and affect local transcription; others travel through the nucleus or cytoplasm and help organise protein complexes. Circular RNAs can act as stable binding platforms for microRNAs or RNA-binding proteins, although the importance of any specific circRNA depends on cell type and experimental context.

Because non-coding RNAs help control gene expression, disruptions in their abundance, sequence or processing can contribute to disease. Cancer is the best-studied example. Some microRNAs act as tumour suppressors by restraining growth-promoting genes, while others can act as oncogenic regulators when overexpressed. Long non-coding RNAs and circular RNAs are also being investigated for roles in tumour growth, metastasis, immune evasion and therapy resistance.

The same principle extends beyond cancer. Altered circulating microRNA profiles have been studied in cardiovascular disease, where they may reflect tissue injury, inflammation or vascular dysfunction. Non-coding RNAs are also under investigation in neurological and infectious diseases, including cases where viruses or host cells use small RNAs and long RNAs to reshape immune responses. These links do not mean that every altered ncRNA causes disease, but they make ncRNAs useful candidates for mechanism studies and biomarker discovery.

Their value as biomarkers comes from a practical advantage: many non-coding RNAs are released into blood and other body fluids and can be stable enough to measure. Distinctive patterns of circulating microRNAs, for example, are being investigated as minimally invasive readouts for cancer, heart disease and other conditions, supporting early diagnosis, prognosis and personalised medicine.

Non-coding RNA biology has reshaped laboratory practice. RNA interference, harnessed by introducing synthetic small interfering RNAs or short hairpin constructs, became a standard way to switch off individual genes and probe their function, complementing genome-editing tools such as CRISPR-Cas9. High-throughput RNA sequencing turned the discovery of new non-coding transcripts into routine work and is a core method of transcriptomics, while chemically modified oligonucleotides let researchers and clinicians target specific RNAs by sequence.

This has translated into approved medicines. Since patisiran became the first FDA-approved RNA-interference drug in 2018, multiple siRNA medicines have reached patients, including therapies for hereditary transthyretin amyloidosis, acute hepatic porphyria, primary hyperoxaluria, hypercholesterolemia and hemophilia. The exact count changes as new approvals and label updates occur, so a disease-based description is more durable than a fixed number. Antisense oligonucleotides that base-pair with target RNAs are also in clinical use, and microRNA mimics and inhibitors have entered clinical trials. These approaches sit within the wider field of RNA therapy and, more broadly, of gene therapy.

The persistent challenge is delivery. Naked RNA is rapidly degraded and does not readily cross cell membranes, so therapeutic non-coding RNAs depend on chemical modification and on carriers such as lipid nanoparticles or ligand conjugates to reach the right tissue. Liver delivery is now comparatively mature because hepatocytes can be targeted efficiently, while delivery to the brain, lung, muscle and many solid tumours remains harder. Off-target effects and unwanted immune activation are additional concerns that shape the design of RNA medicines.

What is the difference between coding and non-coding RNA? Coding RNA, essentially messenger RNA, carries the instructions that ribosomes read to build a protein. Non-coding RNA is transcribed from DNA but is not translated into protein; instead the RNA molecule itself is the functional product. Non-coding RNAs act as structural, catalytic and regulatory molecules, controlling how and when other genes are switched on and off.

Is non-coding RNA the same as junk DNA? No. The phrase “junk DNA” was once applied to genome regions that do not encode proteins, and many of those regions can be transcribed into non-coding RNA. Research has shown that many non-coding RNAs have important biological functions, but function should not be assumed for every detected transcript; it has to be demonstrated experimentally.

What are the main types of non-coding RNA? Non-coding RNAs include housekeeping types that run core cellular machinery, such as ribosomal RNA and transfer RNA, and regulatory types that tune gene expression. Major regulatory classes include microRNA, small interfering RNA, PIWI-interacting RNA, long non-coding RNA and circular RNA, alongside small nuclear and small nucleolar RNAs involved in RNA processing.

Why is non-coding RNA important? Non-coding RNA is important because it helps run the cell's core machinery and regulates when, where and how strongly genes are expressed. These molecules influence protein synthesis, RNA processing, genome stability, development, cell identity and disease mechanisms.

Are non-coding RNAs used as drugs? Yes. Several approved medicines use short synthetic RNAs to exploit the natural RNA-interference pathway and silence disease genes. Other RNA-targeting approaches, including antisense oligonucleotides and experimental microRNA mimics or inhibitors, are part of the broader RNA-therapy field.

How much of the human genome is non-coding? Protein-coding sequences make up roughly 2 percent of human DNA. Large portions of the remaining genome are transcribed into RNA at some point, and many non-coding RNA genes have been catalogued, but estimates vary depending on detection method and on how strictly researchers define biological function.

What is the difference between microRNA and siRNA? Both are short RNAs that silence genes through the RNA-interference machinery. MicroRNAs are encoded in the genome, usually pair partially with their targets and can each influence many messenger RNAs. Small interfering RNAs are usually highly complementary to a target and, in research and medicine, are often introduced synthetically to switch off one specific gene.

Nature Reviews Molecular Cell Biology, Long non-coding RNAs: definitions, functions, challenges and recommendations

Nature Reviews Genetics, Non-coding RNAs in disease: from mechanisms to therapeutics

Cell, Metazoan MicroRNAs

Nature Reviews Drug Discovery, Frameworks for transformational breakthroughs in RNA-based medicines